Bhatt Rama, Chopra Kamal, Vashisht Rohit
District TB Officer, Ramakrishna Mission Free TB Clinic, Karol Bagh, New Delhi 110005, India.
Director, New Delhi Tuberculosis Centre, New Delhi 110002, India.
Indian J Tuberc. 2019 Jan;66(1):105-110. doi: 10.1016/j.ijtb.2018.05.020. Epub 2018 Jun 13.
To assess the impact of providing integrated psycho-socio-economic support to drug resistant tuberculosis (DRTB) patients on the treatment outcome under programmatic conditions.
Retrospective cohort study.
An urban district TB centre in India under the Revised National Tuberculosis Control Programme.
A cohort of 123 patients who started DRTB treatment between June 2010 and May 2013.
Patients started on treatment for DRTB between June 2010 and May 2013 who were provided with the integrated support package for at least 3 months formed the supported group while the other patients of the cohort formed the non-supported group. The treatment outcomes and sputum culture conversion rates were compared between the two groups.
The supported group consisted of 60 patients and the non-supported group of 63 patients. The treatment success rate was found to be significantly higher in the supported group (65% vs 46.03%; p=0.0349). Support duration was significantly associated with lower incidence of death [HR 0.876, 95% CI 0.811-0.947; p=0.0009] and loss to follow up [OR: 0.752, 95% CI 0.597-0.873; p=0.0023]. The treatment failure rate was higher in the supported group (16.66% vs 4.76%) with 60% of the failures in the supported group occurring after 24 months of compliant treatment. There was no significant association found between support duration and treatment failure or sputum culture conversion.
Integrated support seems to significantly increase the treatment success rate and improve survival and treatment adherence of DRTB patients. However, early diagnosis and effective pharmacotherapy are crucial for reducing treatment failures.
评估在项目实施条件下,为耐多药结核病(DRTB)患者提供综合心理 - 社会 - 经济支持对治疗结果的影响。
回顾性队列研究。
印度一个市区结核病中心,隶属于修订后的国家结核病控制项目。
一组123例于2010年6月至2013年5月开始接受耐多药结核病治疗的患者。
2010年6月至2013年5月开始接受耐多药结核病治疗且接受综合支持包至少3个月的患者组成支持组,该队列中的其他患者组成非支持组。比较两组的治疗结果和痰培养转阴率。
支持组有60例患者,非支持组有63例患者。发现支持组的治疗成功率显著更高(65%对46.03%;p = 0.0349)。支持持续时间与较低的死亡率[风险比(HR)0.876,95%置信区间(CI)0.811 - 0.947;p = 0.0009]和失访率[比值比(OR):0.752,95% CI 0.597 - 0.873;p = 0.0023]显著相关。支持组的治疗失败率更高(16.66%对4.76%),支持组中60%的失败发生在规范治疗24个月后。未发现支持持续时间与治疗失败或痰培养转阴之间存在显著关联。
综合支持似乎能显著提高耐多药结核病患者的治疗成功率,并改善其生存率和治疗依从性。然而,早期诊断和有效的药物治疗对于减少治疗失败至关重要。